Market Overview
In a day marked by geopolitical tensions and corporate upheaval, the markets closed with a palpable sense of urgency and uncertainty. The resignation of Nvidia CEO Jensen Huang, a pivotal figure in the global AI boom, sent shockwaves through the tech sector and beyond, underscoring the intricate interplay between macroeconomic forces and corporate dynamics. The day began with Nvidia's shares plummeting as much as 14% following Huang's departure amid scandal, only to recover slightly to a 5.4% decline by the close. This volatility reflected broader market anxieties, as investors grappled with the implications of Huang's exit on Nvidia's leadership and strategic direction. The appointment of CFO Colette Kress as interim CEO provided some stability, but the search for a permanent successor looms large, with Huang's legacy of innovation and controversy casting a long shadow. Amidst this corporate drama, geopolitical tensions escalated, further unsettling markets. President Trump's declaration that the U.S. does not need a deal with Iran exacerbated fears of prolonged conflict, contributing to rising Treasury yields and a stronger dollar. These developments, coupled with persistent inflationary pressures, painted a grim picture for the economic outlook, with gold prices tumbling to a 52-week low. Sector-specific rotations highlighted the day's volatility. While Nvidia's competitors, such as AMD and Broadcom, advanced, benefiting from the chip giant's woes, the broader semiconductor industry faced headwinds. Companies like Micron and CoreWeave suffered, reflecting investor concerns over the sector's future amidst leadership uncertainty and geopolitical risks. The energy sector also felt the ripple effects of geopolitical tensions, with oil prices edging higher on the back of renewed fears over the U.S.-Iran standoff. This, in turn, underscored the interconnectedness of global markets, where geopolitical events can swiftly alter the economic landscape. As the markets closed, the housing sector offered a sobering reminder of the challenges facing the U.S. economy. Sales of previously owned homes fell to a 16-year low, with mortgage rates and inflation dampening buyer enthusiasm. This downturn in the housing market, a critical component of the U.S. economy, highlighted the broader economic headwinds facing investors. Looking ahead, the markets face a complex web of challenges. The search for Nvidia's new leadership, the ongoing U.S.-Iran tensions, and persistent inflationary pressures will continue to test investor resilience. As the geopolitical landscape evolves and corporate narratives unfold, investors will need to navigate a market characterized by uncertainty and volatility. The coming days will be crucial in shaping the trajectory of global markets, with the interplay between macroeconomic forces and corporate developments remaining at the forefront of investor concerns.
In a tumultuous after-hours session, the U.S. stock market was gripped by a confluence of geopolitical tensions and corporate upheaval, with Nvidia's leadership shakeup at the epicenter. The resignation of CEO Jensen Huang sent Nvidia shares into a tailspin, reflecting broader anxieties about the tech sector's future. This volatility was mirrored in sector ETF movements, with the Technology Select Sector SPDR Fund (XLK) dipping by 0.34%, underscoring investor concerns over Nvidia's strategic direction and the broader implications for the tech industry. Meanwhile, Nvidia's competitors, such as AMD and Broadcom, saw gains, highlighting a sector-specific rotation as investors sought refuge in perceived safer bets within the semiconductor space. Geopolitical tensions, exacerbated by President Trump's comments on the U.S.-Iran situation, further unsettled markets, contributing to a stronger dollar and rising Treasury yields. This environment favored the Energy Select Sector SPDR Fund (XLE), which rose by 1.51%, as oil prices edged higher amid renewed fears of conflict. Conversely, the Financials Select Sector SPDR Fund (XLF) fell by 0.72%, reflecting the broader market's sensitivity to rising yields and a stronger dollar, which typically weigh on financial stocks. The broader market sentiment was one of caution, with the Consumer Discretionary Select Sector SPDR Fund (XLY) and the Consumer Staples Select Sector SPDR Fund (XLP) both experiencing declines of 0.44% and 0.43%, respectively. These movements suggest a flight to safety, as investors grapple with inflationary pressures and economic uncertainties. The Industrial Select Sector SPDR Fund (XLI) and the Materials Select Sector SPDR Fund (XLB) also faced declines, highlighting the pervasive impact of geopolitical and economic headwinds across sectors. Looking ahead, the markets are poised for continued volatility as investors navigate the complex interplay of macroeconomic forces and corporate developments. The search for Nvidia's new leadership, ongoing U.S.-Iran tensions, and persistent inflationary pressures will remain key drivers of market sentiment. As these narratives unfold, investors will need to remain vigilant, balancing the potential for sector-specific opportunities against the broader backdrop of uncertainty and risk.
Market Insights
U.S. equities edged higher in subdued trading, with the advance largely driven by tech megacaps, while broader market participation waned. More than two-thirds of the gainers advanced on below-average volume, indicating that institutional desks remained largely on the sidelines despite the green tape. This volume divergence suggests potential tape fragility under light conditions, as most advancers lacked institutional support. High-beta stocks outperformed defensive cohorts, with the median stock achieving only modest gains. Despite the surface-level bullish sentiment, the absence of volume confirmation leaves the market vulnerable to sharp reversals if macroeconomic headlines trigger sudden selling. Mega-caps, with an average return of 0.53% and a beta of 1.06, underperformed relative to the broader market. Beta cohorts exhibited a negative correlation between beta and average return, with high-beta stocks (-1.93%) performing the worst, highlighting the increased risk associated with these assets. This dynamic suggests that while high-beta stocks did the heavy lifting, the broader market's tepid performance reflects underlying concerns. The market's reliance on a narrow set of leaders, coupled with the lack of institutional engagement, underscores the fragility of the current advance, leaving it susceptible to volatility amid shifting economic narratives.
Next Day Option Data
QQQ
SPY
IWM
6-K/8-K Form Update
MXC
Mexco Energy Corporation reported a 67% increase in net income to $945,152, or $0.45 per diluted share, for the six months ended September 30, 2026, driven by a 21% rise in operating revenues to $4,102,157, primarily due to a 43% increase in average oil price. The company anticipates drilling 55 horizontal wells and completing 20 during fiscal year 2027, with $900,000 already expended. Mexco Energy Corporation, focused on the Permian Basin, cautions that forward-looking statements are subject to risks including production variance and oil price volatility.
LGL
The LGL Group, Inc. reported third-quarter 2026 results, with total revenues rising to $1.464 million from $1.108 million in Q3 2025, despite a net loss of $45,000 compared to a net income of $772,000 in the same quarter last year. The company's cash and cash equivalents increased to $87.0 million as of September 30, 2026, from $41.6 million at the end of 2025, bolstered by a rights offering that issued 6,062,714 shares, generating net proceeds of $41.5 million.
APVO
Aptevo Therapeutics Inc. secured compliance by entering into Inducement Letters with warrant holders, resulting in the exercise of existing warrants for approximately $3.0 million in gross proceeds. The transaction, completed on November 12, 2026, also issued new Inducement Warrants for up to 13,888,890 shares at $1.08 per share, potentially raising an additional $15.0 million if fully exercised. Proceeds are earmarked for working capital and general corporate purposes.
CTA-PA
Corteva, Inc. completed the spin-off of its Seed Business into the independent publicly traded company, Vylor Inc., through a pro rata dividend in-kind on November 12, 2026. As a result, Vylor is now the accounting successor to Corteva for financial reporting purposes, with historical financial statements of Corteva becoming those of Vylor for periods prior to the spin-off. Additionally, Corteva reported non-GAAP financial measures for New Corteva for the three and nine months ended September 30, 2026, and 2025, excluding items such as income taxes and separation costs.
ROC
Rank One Computing Corporation reported record quarterly revenue of $8.0 million for the third quarter ended September 30, 2026, marking a 50% year-over-year increase. The company secured significant federal contracts, including a $64.3 million Department of Justice digital evidence contract award, and announced the acquisition of Zuccaro Technical Consulting to expand its ROC Evidence capabilities. ROC's gross margin reached 90% for the second consecutive quarter, reflecting strong software licensing performance and improved revenue mix.
BLNE
Beeline Holdings, Inc. reported a 30% year-over-year revenue increase to $3.0 million for the third quarter of 2026, with a net loss of $3.8 million and an adjusted EBITDA loss improving by 33% to $1.8 million. The company announced a $3 million annualized cost reduction plan and expects a definitive agreement soon for the TYTL merger, aiming to combine AI-powered mortgage and blockchain securitization platforms. Management anticipates challenges from interest-rate fluctuations and plans to focus on margin protection and cost savings.
LGVN
Longeveron Inc. initiated a strategic review process to maximize shareholder value, retaining Lucid Capital Markets as its financial advisor. The company's investigational therapeutic candidate, laromestrocel (Lomecel-B®), is in development for indications including Hypoplastic Left Heart Syndrome (HLHS) and Pediatric Dilated Cardiomyopathy (PDCM). Longeveron requested an FDA meeting to discuss ELPIS II Phase 2b trial results for HLHS, which showed a reduction in major adverse cardiac events despite not meeting the primary efficacy endpoint. Laromestrocel holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, and the company has initiated an IND application for PDCM.
NNUP
Nocopi Technologies, Inc. reported a 763% surge in total revenues to $3.329 million for the fiscal 2026 third quarter, driven by an early license renewal and the Polymeric acquisition. Gross profit rose to $2.203 million, while net income reached $1.397 million, or $0.12 per share, compared to a net loss in the prior year. The company's cash and equivalents stood at $10.278 million, with no debt, and total stockholders' equity increased to $16.149 million.
CAST
FreeCast, Inc. faces imminent delisting from Nasdaq due to the resignation of William P. Jennings, Jr., which disrupted the audit committee's composition. The company plans to utilize the cure period under Nasdaq Listing Rule 5605(c)(4)(B) and aims to appoint a replacement director, Audit Committee Chairperson, and audit committee financial expert by November 17, 2026, to restore compliance.
PAL
Proficient Auto Logistics, Inc. reported a 30.3% increase in total operating revenue to $149.0 million for the third quarter ended September 30, 2026, compared to the same period in 2025. Total operating income was ($3.9) million, a decline from ($0.1) million in the prior year, with adjusted operating income at $0.3 million versus $4.2 million previously. The company delivered 839,036 units, marking a 38.6% increase from Q3 2025. Proficient plans to host an investor conference call on November 12, 2026, to discuss operations and financial results, focusing on closing the earnings potential gap and leveraging the Hansen & Adkins acquisition for growth.
MSGM
Motorsport Games Inc. reported third-quarter 2026 financial results, showing robust growth and profitability. Revenues surged 21.8% to $3.8 million, with gross profit margin improving to 88.0% from 80.7% year-over-year. The company expanded its Le Mans Ultimate content, achieving a record 11,941 concurrent players during a special event, and strengthened its balance sheet with cash and cash equivalents at $5.4 million, the highest since its IPO.
PRSO
Peraso Inc. reported third quarter 2026 financial results, with net revenue declining to $0.3 million due to irregular order patterns among fixed wireless access customers, down from $1.3 million in the prior quarter and $3.2 million in the same quarter of the prior year. Despite the revenue drop, gross margin improved to 78.5% from 63.7% in Q2 2026 and 56.2% in Q3 2025. The company secured a significant $2 million production order in October, marking its largest in six quarters, and raised approximately $10 million through a private placement with Nant Capital, LLC, bolstering its financial position.
NSPR
InspireMD, Inc. announced third-quarter 2026 financial results, highlighting FDA approval for its CGuard Prime system for Transcarotid Arterial Revascularization (TCAR) procedures, expected to double the U.S. market. International revenue rose 9% year-over-year to $2.2 million, while U.S. revenue fell 36% to $32,000 due to a voluntary recall. Total revenue for the nine months ended September 30, 2026, increased 27.1% to $7.4 million, with U.S. revenue growing 56% to $859,000 and international revenue up 24.1% to $6.6 million.
LOB-PA
Live Oak Bancshares, Inc. issued $100 million in 8.750% Fixed Rate Series B Non-Cumulative Perpetual Preferred Stock, with a liquidation preference of $1,000 per share. The issuance, completed on November 12, 2026, involved 4,000,000 Depositary Shares, each representing a 1/40th interest in a share of Series B Preferred Stock. Morgan Stanley & Co. LLC, Keefe, Bruyette & Woods, Inc., RBC Capital Markets, LLC, and UBS Securities LLC underwrote the offering, which was filed with the SEC in a Current Report on Form 8-K.
SPRO
Spero Therapeutics, Inc. reported a third quarter 2026 net loss of $44.3 million, or $0.76 per diluted share, compared to $7.4 million, or $0.13 per share, in the same period in 2025. The company in-licensed SP001, an anti-CD40L antibody, from Innovent Biologics, securing exclusive worldwide rights, excluding Greater China, for its development and commercialization. Spero also closed a $105 million non-recourse, non-dilutive financing with HealthCare Royalty Partners affiliates, preserving potential long-term upside from Utebzi payments owed to GSK, and expects to fund operations into the second half of 2029.
MCAGU
Mountain Crest Acquisition Corp. V (MCAG) completed a business combination with CubeBio Co., Ltd., subject to shareholder approval, involving a merger and share swap. Shareholders approved the Business Combination Agreement and governance changes at a special meeting on November 11, 2026, with 84.22% voting in favor. MCAG's common stock, trading under the symbol MCAG, is listed on Nasdaq.
DMAC
DiaMedica Therapeutics Inc. reported a decrease in cash, cash equivalents, and short-term investments to $34.9 million as of September 30, 2026, from $59.9 million as of December 31, 2025. Current liabilities increased to $7.5 million, resulting in working capital of $28.0 million, down from $55.5 million. The company completed enrollment in key clinical trials and announced a conference call on November 13, 2026, to discuss its business update and financial results.
SIDU
Sidus Space, Inc. has amended its financial statements, expanding the affected periods to include unaudited condensed consolidated financial statements for the quarters ended September 30, 2024, March 31, 2025, June 30, 2025, and September 30, 2025. The company intends to restate these statements in its upcoming Annual Report on Form 10-K for the year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Corrections related to warrant classification, satellite capitalization, and revenue recognition are expected to increase net loss by approximately $12.5 million for 2024, decrease it by $5.5 million for 2025, and increase it by $2.6 million, $1.5 million, and $4.1 million for the first three quarters of 2026.
SMA
SmartStop Self Storage REIT, Inc. agreed to sell 9,372,500 shares of its common stock through forward sale agreements with JPMorgan Chase Bank, National Association, Wells Fargo Bank, National Association, and several underwriters. The sale, completed on November 12, 2026, involved shares initially priced at $35.6125, subject to adjustments. The Forward Sellers borrowed the shares from third parties as part of the transaction.
CV
CapsoVision, Inc. reported third-quarter 2026 financial results, showing revenue of $3.6 million, up from $3.5 million in the same period of 2025, with stable average selling prices. The company's flagship product, CapsoCam Plus, was used by over 184,000 patients worldwide, up from 151,000 a year earlier. CapsoVision received FDA clearance for AI Highlights and launched it in the U.S. to enhance diagnostic capabilities, completed enrollment for the CapsoCam Colon study, and raised $18 million in a registered direct offering, generating $17.8 million in net proceeds.
OLMA
Olema Oncology, Inc. filed an Eighth Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, officially changing its name from Olema Pharmaceuticals, Inc. effective at 4:01 p.m. Eastern Time on November 12, 2026. The company's common stock continues to trade on The Nasdaq Global Select Market under the ticker symbol OLMA, and its principal executive offices have relocated to South San Francisco, CA.
AEMD
Aethlon Medical, Inc. announced second quarter fiscal 2027 results, reporting cash and cash equivalents of approximately $6.5 million as of September 30, 2026. The company faces increased consolidated operating expenses of 77.2% to $2.7 million, primarily due to higher professional fees linked to the proposed merger with North Immunology, Inc. The merger, expected to be completed in a two-step transaction, will see the combined entity operate under the name North Immunology, Inc., with Aethlon's Hemopurifier business potentially monetized through a contingent value rights agreement for shareholders.
NJR
New Jersey Resources Corporation approved its fiscal year 2027 Officer Annual Incentive Plan, targeting annual incentives of 40-60% of base salary for NEOs, excluding the CEO, and 110% for the CEO, with payouts ranging from 0-150% based on performance. The plan includes cash, RSUs, and DRSUs, contingent on company-wide or business unit achievements. Additionally, performance share units tied to total shareholder return and net financial earnings per share were awarded to NEOs, with vesting conditions linked to performance goals and continued employment.
VRCA
Verrica Pharmaceuticals Inc. reported a 11.9% increase in U.S. YCANTH net product revenue to $5.7 million, driving total revenue to $6.9 million in the third quarter of 2026. The company unlocked $27.5 million of non-dilutive growth capital under its credit facility, extending its cash runway through pivotal trials for common warts, with topline data expected in Q1 and Q2 2027. Verrica also announced an exclusive distribution agreement for YCANTH in Israel and appointed an interim Chief Financial Officer.
CADL
Candel Therapeutics, Inc. has entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to sell up to $50 million in shares of its common stock. This agreement, effective November 12, 2026, builds on the previous 2025 Sales Agreement, which had already facilitated the sale of approximately $50 million in shares. In conjunction with this new agreement, Candel Therapeutics filed a prospectus supplement with the SEC to update its registration statement on Form S-3.
XOSWW
XOS, Inc. reported third-quarter financial results for the period ending September 30, 2026, showcasing operational efficiency and improved profitability. The company achieved a 17.0% sequential revenue increase to $5.5 million, with GAAP gross margin expanding to 26.9% from 13.3% year-over-year, and non-GAAP gross margin improving to 34.4% from 7.2% in the prior quarter. XOS also raised $2.8 million under its at-the-market offering program and reduced its convertible debt by $1.5 million, bringing the outstanding balance to $14.0 million.
CVGI
Commercial Vehicle Group, Inc. appointed David Ruppel as President and Chief Executive Officer effective November 9, 2026, and granted him make-whole and long-term incentive equity awards as material inducements. The Inducement Awards include 611,481 restricted shares and 384,552 performance shares, with an initial long-term incentive award of 198,757 restricted shares and 298,136 performance shares, totaling 2,175,614 shares subject to maximum performance. The company issued a press release on November 12, 2026, confirming the awards in compliance with Nasdaq Listing Rule 5635(c)(4).
INVLW
Innventure, Inc. (NASDAQ: INV) reported third-quarter 2026 results, highlighting substantial cost reductions and a leaner organizational structure. The company transitioned AeroFlexx and Refinity away from reliance on Innventure capital while evaluating strategic alternatives for both businesses. Innventure's consolidated balance sheet as of September 30, 2026, shows a significant decrease in total assets to $230,711 thousand, primarily due to reduced current and non-current assets, alongside a corresponding decrease in liabilities, particularly current liabilities, which dropped to $47,423 thousand.
VATE
Innovate Corp. reported a 42.8% increase in third-quarter 2026 revenue to $495.5 million, driven by a $152.2 million growth in the Infrastructure segment, primarily from DBM Global's commercial structural steel activities. The company completed the sale of DBM Global to IES Holdings and its controlling interest in HC2 Broadcasting to CONX, aiming to reduce debt and streamline its portfolio. Net income attributable to common stockholders rose to $15.8 million, or $1.10 per share, from a prior year loss of $9.4 million, or $0.71 per share.
RANI
Rani Therapeutics Holdings, Inc. faces imminent delisting from the Nasdaq Global Market due to its failure to maintain the Minimum Bid Price Requirement for its Class A common stock. Nasdaq has approved a transfer of the listing to the Nasdaq Capital Market and granted an additional 180-day compliance period until May 10, 2027. The company must achieve a closing bid price of at least $1.00 per share for 10 consecutive business days within this period, with potential extension to 20 days, as it explores options to regain compliance.
ANAB
AnaptysBio, Inc. reported fiscal first-quarter results for the period ending September 30, 2026, with Jemperli immunotherapy achieving global net sales of $1.0 billion, marking a 29% year-over-year growth. The company anticipates annualized Jemperli royalties exceeding $390 million by 2029, based on GSK's peak sales guidance. Cash and investments decreased to $153.0 million, primarily due to operating activities, while collaboration revenue fell to $30.3 million, and general and administrative expenses rose to $11.6 million.
MSAIW
MultiSensor AI Holdings, Inc. (NASDAQ: MSAI) reported third fiscal quarter 2026 financial results, with software revenue rising 43% to $0.9 million, accounting for 58% of total revenue. Total revenue reached $1.5 million, down from $1.6 million in the prior quarter, due to lower hardware revenue and discontinued services. The company announced strategic expansions, including a North American rollout across 14 sites and a data center pilot with a global cloud provider.
SREA
Sempra completed the sale of a 45% equity interest in Sempra Infrastructure Partners, LP to affiliates of Kohlberg Kravis Roberts & Co. L.P. and Canada Pension Plan Investment Board, receiving $4.56 billion in cash proceeds. The transaction is expected to yield a gain of approximately $2.80 billion to $3.30 billion, with additional costs of $450 million to $550 million. Following the sale, Sempra retains a 25% interest in the entity, now deconsolidated and accounted for under the equity method. Additionally, Sempra announced the appointment of Justin C. Bird as Executive Vice President and Chief Financial Officer, effective November 13, 2026.
RNA
Atrium Therapeutics, Inc. announced its third-quarter financial results for the period ending September 30, 2026, highlighting key developments. The company dosed the first patient in the Corventis Phase 1/2 clinical trial of ATR 1072 for PRKAG2 syndrome and closed a $50 million private placement, extending its cash runway through 2028 to a pro-forma balance of $293.6 million. Atrium reported $15.3 million in collaboration revenue, primarily from a deal with Bristol Myers Squibb, and anticipates initial proof of concept data from the Corventis trial in the second half of 2027.
TNONW
Tenon Medical, Inc. reported a 22% revenue increase to $1.4 million in Q3 2026, with gross profit rising 23% to $1.0 million, resulting in a 66.3% gross margin. The company raised $15.6 million in gross proceeds, repaid convertible notes, and ended the quarter with $8.3 million in cash. Operating expenses improved to $4.0 million, and Tenon Medical announced the commercial launch of its 3D-printed lateral screw, added eight new U.S. patents, and regained compliance with Nasdaq's requirements following a reverse stock split.
VNRX
VolitionRx Limited reported third quarter 2026 financial results, revealing revenue of approximately $1.6 million, up 157% year-over-year, driven by increased deferred revenue recognition. Operating expenses decreased by 14%, narrowing the operating loss to $3.3 million, a 35% improvement from the prior period. The company's cash and cash equivalents increased to $2.4 million, bolstered by $5.2 million in net proceeds from its at-the-market facility, and it prepaid the outstanding balance of its $7.5 million convertible note.
NEOVW
NeoVolta, Inc. reported a significant revenue increase to $2.8 million for the quarter ended September 30, 2026, up from $13.5 thousand in the previous quarter, driven by sales from its residential energy storage projects. Gross profit rose to $1.0 million, or 36.5% of revenue, reversing a previous gross loss, while GAAP net loss narrowed to $7.7 million, or $(0.13) per share, from $11.7 million, or $(0.24) per share. The company bolstered its financial position with a $20 million senior secured term loan and signed a $116 million master purchase agreement for battery energy storage system (BESS) products.
CBIO
Crescent Biopharma, Inc. reported third-quarter 2026 financial results, showcasing a cash position of $289.4 million as of September 30, 2026, sufficient to fund operations into the second half of 2028. The company completed dose escalation in the global Phase 1/2 ASCEND trial of CR-001, with preliminary antitumor response data expected in Q1 2027, and initiated the first patient dosing in the global Phase 1/2 APOLLO trial of CR-002, expecting initial data in the second half of 2027. Crescent also granted Sichuan Kelun-Biotech exclusive rights to CR-001 in Greater China, with initial Phase 2 trial data anticipated in mid-2027.
MRLN
Merlin, Inc. secured a $8.9 million task order for its C-130J autonomy program with the U.S. Special Operations Command and received a $500,000 contract from U.S. Africa Command for its Autonomous Casualty Evacuation Industry Technology Challenge. The aerospace and defense technology company reported third quarter 2026 total revenue of $3.5 million, up from $2.2 million in the previous quarter, with a GAAP net income of $73.8 million, reversing a loss of $(58.4) million in the second quarter. Cash, cash equivalents, and short-term investments stood at $161.6 million, down from $183.9 million at the end of June 2026.
TACT
TransAct Technologies Incorporated reported preliminary third quarter 2026 financial results, with net sales up 10% year-over-year to $14.4 million. The company revised its 2026 revenue guidance to $55-$56 million and adjusted EBITDA guidance to $1.5-$1.75 million. Despite a decline in Casino and Gaming sales, FST revenue increased 33% to $6.4 million, and FST software revenue grew 61% to $876 thousand, driving a 24% rise in FST recurring revenue.
SLXNW
Silexion Therapeutics Corp announced a reverse share split of its issued and outstanding ordinary shares at a ratio of one post-Reverse Share Split share for every twenty-four pre-Reverse Share Split shares, effective November 10, 2026. The move, approved by shareholders at an extraordinary general meeting, will see the company's shares trading on Nasdaq under the ticker symbol SLXN at the market open on November 11, 2026, with each warrant exercisable for one twenty-fourth of an ordinary share and the Warrant Price adjusted to $372,600.00 per post-Reverse Share Split ordinary share.
BOLT
Bolt Biotherapeutics, Inc. completed the acquisition of Prana Therapies in a stock-for-stock reverse merger and secured $120 million in private placement financing. The transaction positions Prana's pipeline, led by PRA-216, as the company's primary development focus. PRA-216, an IL-4Rα/TSLP bispecific antibody in Phase 2, aims to surpass single-mechanism therapies with potential for infrequent, at-home dosing. The financing supports advancing PRA-216 and the broader INSPIRE pipeline through an anticipated data-rich period.
FDMT
4D Molecular Therapeutics, Inc. reported Q3 2026 financial results, revealing a cash position of $375.0 million as of September 30, 2026, down from $514.0 million at year-end 2025. The company completed enrollment for its pivotal Phase 3 trial in wet AMD, 4FRONT-2, with results expected in H2 2027, and initiated the global Phase 3 4SIGHT program in DME. Additionally, 4D Molecular Therapeutics highlighted positive Phase 2b data from the PRISM trial of 4D-150 in wet AMD and strengthened its regulatory team by hiring Eric Floyd as Chief Regulatory & Quality Officer.
ALMS
Alumis Inc. reported fiscal Q3 2026 results, highlighting advancements in its envudeucitinib pipeline and business updates. The company noted robust clinical responses in a Phase 2 trial for patients with high interferon gene signature, representing most moderate-to-severe systemic lupus erythematosus cases, while acknowledging underrepresentation in the overall trial population. Revenue for the quarter was $1.9 million, down from $2.1 million the previous year, with R&D expenses decreasing to $80.8 million from $97.8 million, reflecting the progression of the clinical program.
AAWH
Ascend Wellness Holdings, Inc. reported third-quarter 2026 financial results, showing net revenue of $130.0 million, a 3.1% sequential increase and 4.2% year-over-year growth. Retail revenue accounted for 75.2% of total net revenue, with Adjusted EBITDA reaching $31.1 million, a 23.9% margin. The company now operates 61 stores, exceeding its target, and achieved positive cash flow from operations of $5.4 million, despite a $19.1 million interest payment.
UAMY
United States Antimony Corporation reported a 16% increase in third-quarter 2026 revenues to $10.1 million, driven by a 10% rise in antimony revenues and a 68% increase in pounds sold. Gross profit expanded to $4.3 million, with gross margin improving to approximately 42% from 23%. The company's net loss for the quarter was $7.9 million, excluding non-cash items, while zeolite segment revenue grew 55% year-over-year. USAC invested $28.4 million in capital expenditures for expansion and modernization, with $12.8 million received from the Department of War's Defense Production Act award to date.
SNAL
Snail, Inc. reported a robust third quarter 2026 financial performance, with net revenues surging 139.2% to $33.1 million, driven by strong sales of ARK titles and Bellwright. Total units sold rose 73.3% to 2.0 million, with ASA contributing significantly to the growth. Net income improved to $6.7 million, reflecting a $17.6 million increase in gross profit, while EBITDA reached $7.2 million, showing a $14.5 million improvement. For the nine months, net revenues grew 42.6% to $80.0 million, with ASA and Bellwright sales driving the increase, and net income improved to $5.8 million.
ELDN
Eledon Pharmaceuticals, Inc. reported its third quarter 2026 financial results, revealing a decrease in cash, cash equivalents, and short-term investments to $69.7 million as of September 30, 2026, from $133.3 million as of December 31, 2025. The company's drug tegoprubart showed significant progress in transplant types, with positive patient-reported outcomes from the Phase 2 BESTOW program. Eledon also received FDA Fast Track designation for tegoprubart in kidney transplantation and cleared the IND application for islet cell transplantation in type 1 diabetes, with plans to initiate the global Phase 3 LEGACY trial in Q4 2026.
USFD
US Foods Holding Corp. has appointed Lisa M. Lambert to its Board of Directors, effective immediately, to enhance governance of technology strategy and execution, including AI initiatives. Lambert, founder and CEO of Whitestone Investors III, LLC, brings extensive experience in technology strategy, digital solutions, AI, and cybersecurity. The appointment follows the Board's expansion to nine directors, aiming to accelerate US Foods' technology roadmap, drive volume growth, and improve supply chain productivity.
STIM
Neuronetics, Inc. issued $28.4 million in notes through an underwriting agreement with William Blair & Company, L.L.C., to sell 18.75 million shares of common stock at $1.60 per share, with an option for additional shares. The offering, expected to close on November 12, 2026, aims to repay part of the outstanding term loans under the Perceptive Facility and fund general corporate purposes. The Perceptive Facility, maturing on July 25, 2029, carries an 11.5% interest rate as of September 30, 2026.
ERAS
Erasca, Inc. reported third-quarter financial results ending September 30, 2026, with cash, cash equivalents, and marketable securities totaling $947.8 million. The company announced FDA Fast Track Designation for ERAS-0015 for metastatic pancreatic adenocarcinoma and completed an upsized financing raising approximately $632.5 million. Erasca anticipates initiating Phase 3 trials in 2027 and 2028, with preliminary data expected in H2 2026 and H1 2027, respectively.
SHIM
Shimmick Corporation reported a 28% quarter-over-quarter revenue increase to $136 million for Q3 2026, driven by Shimmick Projects. The company achieved a gross margin of $17 million, a 487 basis points rise from the previous quarter, and recorded a net income of $1 million, its first positive net income since Q3 2023. Adjusted EBITDA surged 106% quarter-over-quarter to $9 million, with liquidity rising to $53 million and a backlog of approximately $907 million, 98% of which is attributed to Shimmick Projects.
LFTO
Liftoff Mobile, Inc. reported third quarter 2026 financial results that surpassed expectations, with revenue reaching $238 million, an 8% increase quarter-over-quarter and a 32% year-over-year rise. The company's net income was $87 million, marking a $92 million increase year-over-year and $91 million quarter-over-quarter. Adjusted EBITDA stood at $145 million, up 10% year-over-year and 45% quarter-over-quarter, with a margin of 61%, up one percentage point from the prior year.
ADIL
Azora Therapeutics, Inc. reported third-quarter financial results for the period ending September 30, 2026, with a cash position of $22.0 million, down from $28.7 million as of June 30, 2026. The company's net loss widened to $64.6 million, or $4.52 per share, primarily due to a $57.1 million non-cash charge related to milestone warrant rights liability. Research and development expenses rose to $1.8 million, while general and administrative expenses increased to $5.8 million, compared to the same quarter in 2025.
SLSN
Solensence, Inc. reported record third-quarter 2026 financial results, with revenue surging 38% year-over-year to $20.2 million. The company achieved a gross profit of $7.9 million, a gross margin of 39.3%, and a net income of $3.7 million, marking the highest in its history. Solensence completed the primary investment and implementation phase of its operational excellence pillar, enhancing capacity and efficiency to meet robust demand and scale for future growth.
DERM
Journey Medical Corporation reported third quarter 2026 financial results, showcasing total revenues of $19.0 million, an 8% increase from the prior-year quarter, driven by Emrosi® revenue growth of 84%. The company's gross margin improved to 69% from 67%, and GAAP net loss narrowed to $1.3 million, or $(0.05) per share, compared to $2.3 million, or $(0.09) per share, in the same period of 2025. Cash and cash equivalents stood at $22.3 million at the end of September 2026, down from $24.1 million at the end of December 2025.
JCAP
Jefferson Capital, Inc. reported record third-quarter 2026 collections of $319.2 million, a 35% year-over-year increase, and deployments growing 111% to $318.0 million. The Estimated Remaining Collections (ERC) rose 23% to $3.6 billion, with the United States accounting for $2.586 billion. Pre-tax income was $58.9 million, net income $46.9 million, and earnings per share (EPS) $0.76, while adjusted pre-tax income was $63.3 million, adjusted net income $51.3 million, and adjusted EPS $0.83. The company's leverage ratio improved to 1.73x as of September 30, 2026.
JBSS
John B. Sanfilippo & Son, Inc. authorized a $20 million stock repurchase program and declared a special cash dividend of $2.00 per share, returning approximately $24 million to shareholders. The repurchase and dividend, approved by the Board, reflect the company's strong balance sheet and commitment to disciplined capital allocation. These actions are set against a backdrop of consistent cash generation and strategic flexibility for future investments and growth opportunities.
CBRS
Cerebras Systems Inc. reported record financial results for the third quarter ended September 30, 2026, with GAAP revenue of $210.8 million, up 55% year-over-year, and core revenue of $230.9 million, up 70% year-over-year. The company secured 700 gross megawatts of data center capacity for delivery by the end of 2027, expanding its European footprint with contracts in Norway and Finland. Cerebras Systems announced new customer wins, including Oracle and a major cloud deal with a top three hyperscaler, positioning its next-generation systems to deliver significantly enhanced performance by 2027.
ENHA
Enhanced Group Inc. announced definitive agreements to acquire a 77% controlling interest in DEAG Deutsche Entertainment AG via an all-stock transaction, with combined 2027E revenue expected at approximately $670 million and Adjusted EBITDA at $26 million. The company also completed a $15 million equity PIPE and the final closing of a $50 million private placement. Concurrently, Enhanced Group executed exchange share agreements with DEAG shareholders to secure the controlling interest.
VTSI
VirTra, Inc. reported third-quarter financial results for the period ending September 30, 2026, showing significant growth in bookings and backlog. The company's revenue increased to $7.6 million from $5.3 million in the prior year, driven by international system deliveries and improved revenue conversion. Net income was $2.2 million, or $0.19 per diluted share, compared to a net loss of $0.4 million in the prior year, with adjusted EBITDA reaching $2.6 million.
KOD
Kodiak Sciences Inc. reported financial results for the quarter ended September 30, 2026, highlighting significant progress in its drug development pipeline. Zenkuda (tarcocimab tedromer) met primary endpoints in the DAYBREAK and DAYLIGHT studies for wet age-related macular degeneration (wet AMD), showing meaningful vision gains and rapid retinal drying with 54% of patients on a 6-month dosing interval. Additionally, Tabirafusp alfa tedromer met its primary endpoint, maintaining safety profiles consistent with aflibercept. Kodiak Sciences raised $69 million from its at-the-market equity offering, ending the quarter with a cash position of $88.7 million.
TOPP
Toppoint Holdings Inc. faces imminent delisting from the NYSE American due to non-compliance with listing standards, as its stock price has remained low for an extended period. The company's Board of Directors approved a 1-for-5 reverse stock split on November 11, 2026, to address this issue. Toppoint is executing the reverse split, aiming to complete it by November 23, 2026, to regain compliance with listing requirements.
PRHIZ
Presurance Holdings, Inc. reported a significant improvement in underwriting performance for the third quarter of 2026, with a combined ratio of 82.7% compared to 95.2% in the prior year quarter. The company's gross written premiums decreased 57.8% to $6.2 million in Q3 2026, reflecting disciplined underwriting amid potentially softening market conditions. Personal lines business continued to generate profitable results, with book value per share at $6.45 as of September 30, 2026, down from $14.49 in prior periods.
KOYNU
First Digital Acquisition Corp Ltd. has successfully rebranded from CSLM Digital Asset Acquisition Corp III, Ltd following shareholder approval at its annual general meeting. The company's name change and adoption of the third amended and restated memorandum and articles of association were approved with approximately 86.3% of the votes cast. First Digital Acquisition Corp Ltd. plans to apply to Nasdaq to update its trading symbols to FDXGU, FDX, and FDXW, respectively.
ZSTK
ZeroStack Corp. dismissed Davidson & Company, LLP as its independent registered public accounting firm effective November 5, 2026, due to incomplete interim review procedures. The company requested and received a letter from Davidson confirming agreement with its disclosures on November 12, 2026. L J Soldinger Associates, Certified Public Accountants, were appointed on November 6, 2026, to review and audit ZeroStack's financial statements for the third quarter and full year ending December 31, 2026.
BRUNW
Boost Run Inc. reported its third quarter 2026 results, highlighting a 496% year-over-year increase in revenue to $39.9 million and $2.7 billion in total contracted revenue. The company secured approximately $600 million in non-dilutive project-based financing and $482 million in customer prepayments, with all $2.7 billion in TCV either live, in current deployment, or fully contracted. Boost Run completed the redemption of all outstanding public and private warrants in August 2026, maintaining $157 million in unrestricted cash and aiming for sustainable net cash flow margins of 15-20% in forward periods.
UPWK
Upwork Inc. announced a Restructuring Plan to enhance operational efficiency and drive profitable growth, targeting a workforce reduction of approximately 37% by early 2027. The company expects to incur $27 million to $37 million in pre-tax restructuring charges, primarily for severance and termination costs, with most charges recognized over the next three quarters. The Board expanded the plan on November 10, 2026, identifying further cost-saving opportunities, with charges anticipated through September 30, 2026, subject to local law requirements.
MRVL
Marvell Technology, Inc. has expanded its Board by appointing three new independent directors, effective November 12, 2026, increasing the total to ten directors. The additions include Donna C. Morris from Walmart, Douglas R. Bettinger from Lam Research, and Sasan K. Goodarzi from Intuit, bringing expertise in talent strategy, semiconductor finance, and operational management. These appointments aim to bolster Marvell's strategic capabilities as it navigates a period of significant growth driven by rising demand for AI infrastructure.
RKT
Rocket Companies has appointed Adam Blitzer, Chief Operating Officer of Datadog, as an independent director to its Board of Directors. Blitzer, a technology entrepreneur with extensive experience in scaling global platforms and implementing AI solutions, strengthens Rocket's strategic direction as the company integrates AI across its homeownership services. His expertise is expected to enhance Rocket's AI-driven initiatives, which already handle 65% of inbound servicing calls and expedite credit processes for nearly 20% of its direct-to-consumer volume.
TGEN
Tecogen Inc. reported a 9.6% increase in overall revenue for the third quarter of 2026, driven by a 13% rise in service revenues and a 2% increase in product revenue. Adjusted EBITDA surged by 39.8% year-over-year, bolstered by higher service revenues and reduced costs, with the dual power source module retrofit highlighted as a key growth driver. The company anticipates further improvements in service margins and expects additional deposits in Q4.
MPTI
M-tron Industries, Inc. reported a third-quarter 2026 revenue increase of 11.1% to $15.7 million, with net income rising 66.4% to $3.0 million or $0.70 per diluted share. The company's nine-month results showed revenues of $45.5 million, net income of $7.3 million or $1.79 per diluted share, and adjusted EBITDA of $10.2 million. Backlog grew 44.3% year-over-year to $84.9 million as of September 30, 2026.
NVDA
NVIDIA Corporation announced Jensen Huang's immediate resignation as President, Chief Executive Officer, and Board member, appointing Colette M. Kress as interim CEO. Harvey C. Jones, age 73, was named the first-ever Chair of the Board. The Board is conducting a search for a permanent CEO, considering both internal and external candidates.
MTVA
MetaVia Inc. announced positive interim results from its Phase 1 clinical trial of DA-1726, a novel oxyntomodulin analog. The trial showed a statistically significant 1.47 mg/dL placebo-adjusted reduction in serum uric acid, a 68.1% reduction in liver fat, and a 13.5% placebo-adjusted weight loss after 16 weeks of treatment in adults with obesity. MetaVia is advancing DA-1726 toward a planned Phase 2 study in MetALD and ALD, set to begin in the second half of 2027.
CTVA
Corteva, Inc. reported third-quarter 2026 results, showcasing strong new product sales growth and operational excellence amid market challenges. Net sales decreased 1%, with organic sales down 4%, driven by lifecycle pressures in Brazil and U.S. pricing declines. Pro Forma GAAP income was $112 million, with EPS at $0.16, while Adjusted Pro Forma Operating EBITDA reached $943 million, expanding the margin to 17.6%. The Board authorized the first dividend post-spin, updating full-year guidance to $1.1-$1.125 billion in Adjusted Pro Forma Operating EBITDA and $0.76-$0.80 in EPS, reflecting softer market conditions in Brazil.
EFC-PC
Ellington Financial Inc. completed the sale of mortgage servicing rights-related investments, monetizing all material assets from the 2023 acquisition of Arlington Asset Investment Corp. The transaction, executed above the September 30, 2026 carrying value, freed up over $75 million in cash, enhancing financial flexibility. CEO Laurence Penn noted that redeploying capital into core strategies offers more attractive returns given current market pricing.
AENTW
Alliance Entertainment Holding Corporation reported first quarter fiscal 2027 revenue growth of 10% to $278.8 million, with gross profit increasing 13% to $42.1 million and gross margin expanding 50 basis points to 15.1%. Net income rose 56% to $7.6 million, and GAAP diluted EPS increased 50% to $0.15. Physical movie revenue grew 20%, vinyl revenue rose 14%, and CD revenue increased 22%, while collectibles revenue surged 87%. Interest expense decreased 49% to $1.2 million, and operating cash flow increased 58% to $4.3 million.
NTRP
NextTrip, Inc. has expanded its cruise category through initiatives integrating media, technology, and travel businesses, including cruise-focused programming on JOURNY TV and Storybook cruise booking tools. The company aims to enhance the cruise planning process for U.S. consumers, offering targeted advertising opportunities for cruise lines. This expansion builds on the growth of its Five Star Alliance cruise business, with bookings for sailings departing in 2027, 2028, and 2029, potentially accelerating cruise bookings over time.
VANI
Vivani Medical, Inc. announced third-quarter 2026 financial results and provided a business update. The company anticipates announcing top-line results from its ongoing Phase 1 study of low-dose NPM-139, a semaglutide implant, later this week. Vivani recently entered into a definitive agreement to merge with ClearOne, Inc., subject to final regulatory approval, expected to close shortly after approval is received. Additionally, Vivani signed an agreement with Novo Nordisk to evaluate NPM-139, its semaglutide drug implant for chronic weight management, with no exclusivity provisions. Vivani's cash position as of September 30, 2026, was $15.5 million, down from $20.8 million as of June 30, 2026.
MOVE
Corvex, Inc. reported a 31% increase in third-quarter 2026 revenue to $5.0 million, with nine-month total revenue reaching $9.3 million. Deferred revenue surged to $3.2 million as of September 30, 2026, from $12,000 at year-end 2025. The company secured approximately 8 MW of critical IT capacity, with 1.5 MW live, and raised $33 million through a private placement of 4.26 million shares.
TRMK
Trustmark Corporation and Hancock Whitney Corporation have agreed to merge, with Hancock Whitney continuing as the surviving entity. The transaction, valued at a substantial deal size, is expected to close in the first quarter of 2027, contingent on regulatory and shareholder approvals. Amid regulatory scrutiny, the merger carries significant financial implications for both companies and their shareholders, with potential risks affecting the timing and success of the transaction.
SES-WT
SES AI Corporation ramped up its Chungju line to produce 1 million NDAA-compliant cells per year by October, with production and delivery to customers now underway. The company reported a GAAP net loss of $13.4 million in the third quarter, a 25% decrease from the previous quarter's $17.9 million, while maintaining its full-year 2026 revenue outlook of $30 million to $35 million. SES AI also released Molecular Universe 4.0, a battery materials discovery platform, and highlighted its energy storage systems and drone cells as key growth drivers.
DXYN
The Dixie Group, Inc. has reported a notable increase in net sales, reaching $338 million in 2024, driven by growth in high-end residential sales across its brands. The company's business is influenced by remodeling, existing home sales, and new construction, focusing on the mid to high-end residential replacement segment. Despite challenges such as the loss of a major customer and rising raw material costs, The Dixie Group has implemented cost reduction strategies and aims to improve gross margins, anticipating strong sales with potential interest rate reductions.
TOVX
Theriva Biologics, Inc. completed the sale of its antibiotic-degrading enzyme portfolio, including SYN-004, to Biossil Labs Inc. for $350,000 upfront and up to $91 million in milestones, plus royalties. The company reported $8.5 million in cash and cash equivalents as of September 30, 2026, with patient enrollment in the VIRAGE2 Phase 2a trial progressing well, expected to complete by Q4 2026. Theriva continues to evaluate strategic alternatives to maximize shareholder value.
CMIIW
Inflection Point Acquisition Corp. VII agreed to amend its merger agreement with Elroy Air, Inc. The amendment streamlines stock exchange procedures, eliminating the need for holders of Elroy Air stock to surrender certificates for merger consideration, which will be delivered in book-entry form. Additionally, the amendment modifies lock-up agreement requirements, extending them to certain Elroy Air employees post-merger, ensuring a smoother transition and compliance with closing conditions.
AVLN
Avalyn Pharma Inc. reported a third-quarter net loss of $29.7 million for the period ending September 30, 2026, compared to $23.6 million in the same quarter of 2025. The company's cash position stands at $386.6 million, with a runway projected into 2029, supported by increased R&D expenses of $25.5 million due to ongoing clinical trials. Avalyn initiated a Phase 1 trial of AP03, a fixed-dose combination of pirfenidone and nintedanib, with enrollment expected in the second half of 2026, and appointed Robert J. Meyer, MD, to its Board of Directors in September 2026.
PROF
Profound Medical Corp. announced leadership changes and board policy amendments on November 5, 2026. Cynthia Lavoie resigned as a director, with Jason Mills appointed as her replacement, while Richard R. Fabian transitioned to President and CEO, and Arun Menawat became Executive Chairman. Matthew Sobczyk was appointed CFO, succeeding Menawat's interim role. The board also approved a new non-employee director compensation policy, effective January 1, 2027, including a $55,000 annual retainer and a one-time $110,000 long-term incentive grant.
WU
The Western Union Company terminated its agreement to acquire International Money Express, Inc. (IMXI) due to unmet conditions from California's Department of Financial Protection and Innovation, which required significant changes to its business model and strategy. The termination, effective at 12:00 a.m. Eastern time on November 12, 2026, incurs no fee, but IMXI has contested the validity of the notice, threatening legal action if the merger is not completed.
AKTS
Aktis Oncology, Inc. (NASDAQ:AKTS) reported third-quarter financial results, highlighting the initiation of its third Phase 1b clinical trial, BActinium-2, to evaluate AKY-2519 in lung cancer and other B7-H3 expressing tumors. The company also began first backfill cohorts in ongoing trials for AKY-1189 and AKY-2519. Aktis' cash position as of September 30, 2026, stood at $492.9 million, up from $226.8 million a year prior, reflecting net proceeds from its January 2026 IPO, offset by operational cash use.
TOIIW
Starling Oncology has successfully refinanced its $86M note with OrbiMed, strengthening its balance sheet and expanding revolver capacity to $25M. In Q3 2026, the company reported revenue of $170M, a 24% increase YoY, with a specialty pharmacy gross margin of 24% and MLR declining 400bps to 81% QoQ. Starling Oncology's financial outlook projects FY26 revenue of $650-$660M and adjusted EBITDA of $4-$6M, while launching Starling Oncology Nexus to enhance provider engagement and clinical pathway adherence.
ONCY
Oncolytics Biotech Inc. has entered a clinical supply agreement with Coherus Oncology, Inc. to assess the combination of Oncolytics' investigational oncolytic virus immunotherapy, pelareorep, with Coherus' PD-1 inhibitor, LOQTORZI, in a study targeting squamous cell anal carcinoma patients who have progressed on standard first-line treatments. The study, set to commence in Q1 2027, aims to explore enhanced antitumor activity in patients with no approved second-line therapies, building on pelareorep's previous efficacy signals in later-stage SCAC patients.
MNPR
Monopar Therapeutics Inc. reported third-quarter 2026 financial results and provided business updates. The company presented baseline findings from the Phase 3 FoCus study of ALXN1840 at the American Association for the Study of Liver Diseases meeting. Monopar announced the appointment of Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs, and initiated the rolling submission of an NDA for ALXN1840 to the FDA, with completion expected in the coming weeks. As of September 30, 2026, Monopar's cash, cash equivalents, and investments totaled $129.4 million, expected to support operations through at least March 31, 2028.
HWCPZ
Hancock Whitney Corporation and Trustmark Corporation agreed to merge, with Trustmark merging into Hancock Whitney, expected to close in late Q1 2027 pending regulatory and shareholder approvals. The $6.25 billion transaction involves issuing subordinated notes and carries potential financial implications, including compliance with Nasdaq listing requirements and SEC disclosure rules. The merger's success hinges on overcoming regulatory, market, and integration challenges, which could impact anticipated benefits and timelines.
IRHOU
Iron Horse Acquisition II Corp. has agreed to a business combination with Electra Vehicles, Inc., positioning Electra as the Official Battery Intelligence Partner of Westbrook Racing at the E1 Miami GP 2026. The transaction, utilizing Electra's AI Brain for Batteries platform, will be submitted to IRHO shareholders for approval, with a registration statement on Form S-4 filed with the SEC. Upon approval, securities are expected to be issued under the ticker symbol "AIBR" on The Nasdaq Stock Market.
APOS
Apollo Global Management, Inc. announced a Fixed Income Investor call hosted by its subsidiary, Athene Holding Ltd., on November 12, 2026, at 9:00 a.m. ET, featuring updates on business trends and investment portfolios. The call will be accessible via Athene's website and a toll-free number, with a live webcast and replay available. Additionally, Apollo issued a new series of 7.625% Fixed-Rate Resettable Junior Subordinated Notes due 2053, trading on the New York Stock Exchange.
HYFM
Hydrofarm Holdings Group, Inc. (HYFM) regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement, following the elimination of $109 million in debt on October 27, 2026. The company completed a registered direct offering and private placement to restore positive equity, confirmed by Nasdaq after a hearing. HYFM will monitor its equity and other listing requirements, subject to a Mandatory Panel Monitor until November 9, 2027.
SGMT
Sagimet Biosciences Inc. announced positive Phase 3 clinical trial results for denifanstat in moderate to severe acne, with data presented at EADV 2026 and Fall Clinical Dermatology 2026. The company completed an underwritten offering of Series A common stock, raising $115 million, and reported a pro forma cash balance of approximately $356 million as of September 30, 2026, expected to fund operations through mid-2029. Sagimet also initiated its pivotal U.S. AURORA Phase 3 trial, with topline data expected in the second half of 2027, and continues developing a topical FASN inhibitor for acne treatment.
LW
Lamb Weston Holdings, Inc. agreed to settle a class action alleging its operations contributed to nitrate contamination in the lower Umatilla River basin, agreeing to pay $25 million into a fund for regional property enhancements and water-related expenses. The settlement, pending U.S. District Court approval, does not admit liability, and the expense has been accrued as a current liability as of August 30, 2026. Lamb Weston expects to pay into the fund in the second half of its fiscal year 2027.
LUNR
Intuitive Machines, Inc. reported record financial performance for the third quarter ended September 30, 2026, with revenue of $269 million and a gross margin of 26%. The company secured a $10 billion IDIQ contract for the next-generation Commercial Lunar Payload Services 2 (CLPS 2) and additional awards totaling $450 million. Intuitive Machines expanded its Near Space Network cislunar constellation and booked a record backlog of $1.9 billion, up $1.7 billion from year-end 2025. The company expects full-year 2026 revenue of $920 - $950 million and positive Adjusted EBITDA.
WPRT
Aetherion Technologies Inc. reported a 60% revenue increase to $2.6 million in Q3 2026, driven by strong demand for LNG HPDI trucks and growth in product and aftermarket revenue. The company's heavy-duty trucking division, Cespira, saw a 46% revenue rise to $2.6 million, reducing its net loss by $5.7 million. Aetherion reduced capital contributions to Cespira from $11.0 million to $2.8 million, with the HPDI 3.0 fuel system production set to begin in Q4 2026.
STN
Stantec reported strong third-quarter 2026 results, with net revenue increasing 9.4% year-over-year to $1.9 billion, driven by organic growth of 5.3% and acquisition growth of 2.6%. Adjusted EBITDA rose 16.6% to $53.7 million, with the margin reaching 20.2%, up 120 basis points from Q3 2025. The company raised its 2026 targets for net revenue growth and adjusted EPS, with net revenue growth expectations narrowed to 9.0% to 11.0%. Stantec also announced the acquisition of Niche, a 200-person engineering and environmental consultancy firm in Australia, and declared a dividend of $0.245 per share.
ARIS
Aris Mining Corporation filed a Form 6-K report for November 2026, disclosing financial metrics, deal sizes, litigation, executive shifts, and Nasdaq compliance status. The company released a NI 43-101 Technical Report for the Toroparu Project, detailing forward-looking information on capital, operating, and closure costs, as well as projected economic results. Aris Mining also announced a change in its Chief Legal Officer to Ashley Baker.
SLI
Standard Lithium Ltd. announced positive preliminary economic assessment results for its Franklin Project in Arkansas, highlighting a $5.9 billion unlevered pre-tax net present value and a 25.7% internal rate of return. The company secured long-term commercial agreements with LG Energy Solution and Trafigura for the SWA Project, committing up to 20,000 tonnes per year for 10 years. Standard Lithium also appointed Ralph Alexander as an independent board member, leveraging his extensive experience in global energy and infrastructure sectors.
PRFX
PRF Technologies Ltd. faces imminent delisting from Nasdaq after its shares traded below the US$1.00 minimum bid price for 30 consecutive days. The company has requested a hearing to present a compliance plan, potentially including a reverse share split, with a possible 180-day exception to meet the requirement. PRF Technologies, focusing on healthcare and sustainable energy, holds approximately US$11.0 million in cash and is advancing its OcuRing™-K Phase 2 trial and GridFeed transaction with Dotz.
LICN
Lichen International Limited issued $3.5 million in notes through a registered direct offering, closing on November 11, 2026. The company sold 17.5 million units, each comprising a series A ordinary share and a warrant, to raise funds for working capital and general corporate purposes. Concurrently, officers and directors entered lock-up agreements, restricting share sales for 90 days post-offering.
TCMFF
Telecom Argentina S.A. reported consolidated results for the nine-month period ended September 30, 2026, and the third quarter of fiscal year 2026, with figures adjusted for inflation under IAS 29. The company's market capitalization stood at USD 4,557.2 million as of November 11, 2026. In 3Q26, consolidated revenues reached USD 1,778 million, up 18% from 3Q25, with service revenues at USD 1,714 million, a 19% increase. EBITDA for the quarter was USD 642 million, a 37% rise, with a margin of 36.1%. Net debt decreased to USD 2,927 million, a 9% reduction from 3Q25, with net leverage at 1.2x.
AFYA
Afya Limited reported a 6.1% year-over-year revenue increase to R$985.2 million in Q3 and a 6.7% rise to R$2,970.0 million for the nine months ended September 30, 2026. Adjusted EBITDA grew 8.7% YoY to R$433.8 million in Q3 and 4.6% YoY to R$1,351.8 million for the nine months, with margins of 44.0% and 45.5%, respectively. Net income rose 7.2% YoY to R$171.0 million in Q3 and 6.9% YoY to R$634.0 million for the nine months. The company reaffirmed its full-year guidance and entered into a binding merger agreement with Yduqs Participações S.A., pending approvals.
NU
Nu Holdings Ltd. reported robust Q3'26 financial results, with total portfolio growth of 39% unsecured and 23% secured, driven by disciplined underwriting. The company's deposits across Latin America increased by 19% in Brazil, 6% in Mexico, and 5% in Colombia year-over-year, while the cost of deposits decreased significantly. Nu Holdings Ltd. maintained strong profitability with a net income of US$783 million and a net interest income margin of 22.9%.
MDXH
MDxHealth SA reported its third quarter 2026 financial results, showing revenue of $22.7 million, unchanged from the prior year, with a 9% increase in cost of sales to $8.7 million. The company faced an operating loss of $8.1 million, up from $4.4 million, due to higher expenses from the ExoDx acquisition, and a net loss increase of 26% to $12.3 million. Adjusted EBITDA turned negative at ($6.3) million, compared to a positive $0.9 million previously. Following Eric Bednarski's board resignation, the Chief Commercial Officer position was eliminated, and sales and marketing now report directly to CEO Michael K. McGarrity. MDxHealth discontinued its Resolve UTI business and is restructuring its commercial organization to focus on growth in 2027.
NNOX
NANO-X Imaging Ltd. secured compliance by entering into two Standby Equity Purchase Agreements (SEPAs) with YA II PN, Ltd., a Cayman Islands exempt limited company, for the potential sale of up to $50 million in Ordinary Shares. The agreements allow for sales on a private placement and registered primary offering basis, with the purchase price set at 97% of the daily volume-weighted average price, subject to certain conditions. NANO-X Imaging Ltd. agreed to pay structuring and commitment fees totaling $515,000 in Ordinary Shares, with the sale of shares under the Primary SEPA to be registered under the company's Form F-3 registration statement.
COOTW
Australian Oilseeds Holdings Limited approved a series of capital restructuring measures at an extraordinary general meeting on November 10, 2026. The company consolidated shares at an 80-for-one ratio, reduced par value to US$0.000001, and increased authorized shares to 999,312,500 class A ordinary shares, 625,000 class B ordinary shares, and 62,500 preference shares. Directors were authorized to execute documents to implement these changes.
MTA
Metalla Royalty & Streaming Ltd. reported a net income of $1,553,000 for the nine months ended September 30, 2026, reversing a net loss of $1,838,000 in the same period of 2025. Total assets rose to $276,150,000, while total liabilities decreased to $17,226,000, boosting equity to $258,924,000. Revenue from royalty interests surged to $13,228,000, up from $8,416,000, as cash and cash equivalents increased to $13,450,000.
RUBI
Rubico Inc. has agreed to acquire shares of two special purpose vehicles (SPVs) involved in shipbuilding contracts for two 47,499 dwt chemical/product oil carriers, scheduled for delivery in late 2028 and 2029. The SPVs have secured time charters with Trafigura Maritime Logistics Pte Ltd for seven years, with options to extend for four more years, creating a potential gross revenue backlog of approximately $150.9 million. The total purchase price for 100% of the SPVs' shares is $14.5 million, payable in cash or partially in Series G Preferred stock.
SSYS
Stratasys Ltd. reported a $5.7 million increase in third-quarter 2026 revenues compared to the same period in 2025, driven by higher demand for systems and services despite macro-economic pressures. The company has strengthened its market position through strategic acquisitions, including Origin Laboratories, Xaar 3D, and Covestro, and expanded its offerings with high-speed resin 3D printers from Nexa3D. Additionally, Stratasys executed a share repurchase program and completed a private investment in public equity transaction, reflecting its ongoing commitment to shareholder value.
NRRWF
NuRAN Wireless Inc. has approved a strategic growth plan to expand its Network-as-a-Service (NaaS) portfolio into a recurring infrastructure revenue base, targeting approximately 2,000 cumulative towers by 2028. The plan emphasizes disciplined financing, deployment, and the development of complementary businesses like NuEnergy and NuRAN EDGE. NuRAN aims to maintain equity financing discipline, evaluate debt financing options, and explore partnerships and acquisitions to enhance execution and returns.
EDRY
EuroDry Ltd. reported a 34.9% increase in total net revenues to $19.4 million for Q3 2026, driven by a 55.3% rise in time charter equivalent rates. Net income attributable to controlling shareholders reached $6.9 million ($2.43 per share), up from $3.9 million ($1.38 per share) in Q3 2025. For the nine-month period, total net revenues grew 6.1% to $49.9 million, with adjusted net income at $14.0 million ($4.98 per share), up from $9.2 million ($3.20 per share) in the same period of 2025.
NBIS
Nebius Group N.V. reported a significant revenue surge, issuing unaudited consolidated financial results for the third quarter ended September 30, 2026. Revenues soared to $980.8 million, marking a 571% increase from $146.1 million in the same period of 2025, while adjusted EBITDA improved to $465.8 million from a loss of $5.2 million. The company achieved an adjusted net income of $90.9 million, reversing a net loss of $100.4 million in Q3 2025, despite operating costs rising by 237% to $930.4 million.
KLAR
Klarna Group plc has appointed Chris Koegel as Chief Financial Officer, effective January 1, 2027, succeeding Niclas Neglen. Koegel, joining from Robinhood Markets Inc., where he significantly contributed to the company's growth, brings extensive experience from LPL Financial LLC and Bain & Company. Klarna, with over 120 million global active users, aims to enhance its AI-powered payment solutions and drive long-term growth for shareholders.
FCHL
Fitness Champs Holdings Limited consolidated its share capital through a First Share Consolidation, where every two issued and unissued Class A, B, and preferred shares were merged into one share with double the par value, subject to Nasdaq compliance. The company also adopted the Fourth Amended and Restated Memorandum and Articles of Association to reflect this consolidation. Additionally, a conditional Second Share Consolidation was approved, allowing every hundred Consolidated Class A, B, and Preferred Shares to be merged into one share with a new par value of $0.45, contingent upon receiving at least $5 million from a public offering by December 15, 2026, and submitting a completed Company Event Notification Form to Nasdaq by the same date.
PYPD
PolyPid Ltd. secured $30 million in upfront and near-term milestone payments from Azurity, contingent upon FDA acceptance of the New Drug Application for D-PLEX™20™20, a surgical site infection prevention product. The company is preparing for the U.S. commercial launch of D-PLEX™20™20 in early 2027, subject to FDA approval, and unveiled its "PolyPid 2030" growth strategy, introducing PD01B for diabetic foot infections. PolyPid reported a net loss of $5.8 million for Q3 2026, an improvement from the $7.5 million loss in the same period in 2025.
STKE
SOL Strategies Inc. reported a 19% increase in Houdini Swap's transaction volume to US$106 million in October 2026. The company rebranded its platforms, moving from houdiniswap.com to houdini.com, highlighting its status as a Nasdaq-listed subsidiary. Houdini Swap, a non-custodial, privacy-focused cross-chain swap aggregator, has processed over US$3 billion in cumulative transaction volume, offering capabilities beyond swapping, such as sending, paying, and splitting, with more features planned.
DRTSW
Alpha Tau Medical Ltd. announced plans to host a conference call and webcast on November 16, 2026, to discuss interim results from the REGAIN trial, a U.S. study on its Alpha DaRT therapy for recurrent glioblastoma. The trial, led by principal investigator Dr. Joshua Palmer, aims to assess the feasibility and safety of the treatment in up to 20 patients who have undergone prior CNS radiation. The call will feature insights from CEO Uzi Sofer, Chief Medical Officer Robert Den, MD, and CFO Raphi Levy.
CLGN
CollPlant Biotechnologies Ltd. announced its ordinary shares will begin trading on Nasdaq under the new ticker symbol "OPHI," effective at the open of trading on November 13, 2026. The ticker symbol change reflects CollPlant's strategic expansion into photonic computing, building around LightSolver's all-optical Laser Processing Unit (LPU) technology. CollPlant intends to change its name to OptiPhi Computing Ltd., subject to shareholder approval and regulatory consent, while its shares will continue to be listed on Nasdaq with an unchanged CUSIP number.
GNS
Genius Group Limited faces a trading halt on NYSE American due to an abnormally low share price. The company is actively working with NYSE American to resume trading and plans a 1-for-10 share consolidation to restore its share price. The consolidation is set to take effect at 12:01 a.m. Eastern Time on November 20, 2026, with trading expected to resume on a split-adjusted basis under the existing symbol "GNS".
JZ
Jianzhi Education Technology Group Company Limited announced plans to hold an extraordinary general meeting on December 14, 2026, to vote on a capital reduction resolution. The resolution, in compliance with the Cayman Islands Companies Act, involves reducing the par value of each Class A and Class B ordinary share from US$0.0001 to US$0.0000000001, effectively cancelling the paid-up capital to the extent of US$0.0000999999 per share. Following the resolution, the authorized share capital will increase significantly, with each Class A and Class B share subdivided into one million new shares, resulting in a total of 800 trillion and 200 trillion shares, respectively.